Omnicell's (OMCL) Central Pharmacy Dispensing Service Selected by Tucson VA Medical Center
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Omnicell (OMCL) PT Raised to $155 at Cantor Fitzgerald
November 2, 2021 11:38 AM EDTCantor Fitzgerald analyst Steven Halper raised the price target on Omnicell (NASDAQ: OMCL) to $155.00 (from $135.00) while maintaining a Neutral rating.
The analyst commented, "We reiterate our Neutral rating on OMCL shares but increase our 12-month, DCF-based price target to $155 (compared to $135 previously). This morning, November 2, the company reported 3Q21 results that were ahead of our estimates and FactSet consensus. Revenue was $296 million compared to our estimate of $284 million. Revenue... More
Omnicell (OMCL) Tops Q3 EPS by 17c
November 2, 2021 7:35 AM EDTOmnicell (NASDAQ: OMCL) reported Q3 EPS of $1.08, $0.17 better than the analyst estimate of $0.91. Revenue for the quarter came in at $296 million versus the consensus estimate of $284.74 million.
GUIDANCE:
Omnicell sees FY2021 EPS of $3.80-$3.85, versus the consensus of $3.73. Omnicell sees... More
